Biohaven Ltd. $BHVN Holdings Decreased by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. reduced its stake in Biohaven Ltd. by 63.6% in the first quarter, leaving it with 14,000 shares worth $337,000.
• Other institutional investors have shown varying trends, with Parallel Advisors LLC significantly increasing its holdings by 319.8% during the same period.
• Biohaven's stock has fluctuated, recently opening at $15.70, with a market cap of $1.66 billion and a consensus rating of "Buy" from analysts.

Capital Fund Management S.A. lowered its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 63.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,000 shares of the company's stock after selling 24,488 shares during the quarter. Capital Fund Management S.A.'s holdings in Biohaven were worth $337,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farallon Capital Management LLC lifted its stake in shares of Biohaven by 21.6% in the 4th quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company's stock worth $165,392,000 after acquiring an additional 785,578 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Biohaven by 12.1% in the 4th quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company's stock worth $260,735,000 after acquiring an additional 756,032 shares during the period. Fiera Capital Corp acquired a new stake in shares of Biohaven in the 1st quarter worth approximately $13,983,000. Suvretta Capital Management LLC lifted its stake in shares of Biohaven by 8.1% in the 4th quarter. Suvretta Capital Management LLC now owns 5,620,271 shares of the company's stock worth $209,917,000 after acquiring an additional 421,052 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Biohaven by 160.7% in the 4th quarter. Wellington Management Group LLP now owns 634,055 shares of the company's stock worth $23,682,000 after acquiring an additional 390,888 shares during the period. Institutional investors own 88.78% of the company's stock.

Biohaven Trading Down 1.1%

Shares of NYSE BHVN traded down $0.17 during mid-day trading on Monday, hitting $15.35. 999,656 shares of the company traded hands, compared to its average volume of 1,951,986. Biohaven Ltd. has a 1 year low of $12.79 and a 1 year high of $55.70. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -2.00 and a beta of 1.02. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 1.91. The business has a 50 day moving average of $14.51 and a two-hundred day moving average of $19.83.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($1.94) EPS for the quarter, meeting the consensus estimate of ($1.94). On average, sell-side analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of research analyst reports. Bank of America lowered their target price on Biohaven from $50.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Cantor Fitzgerald raised Biohaven to a "strong-buy" rating in a report on Tuesday, May 13th. Morgan Stanley lowered their target price on Biohaven from $63.00 to $54.00 and set an "overweight" rating on the stock in a report on Tuesday, August 12th. Robert W. Baird lowered their target price on Biohaven from $57.00 to $52.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price (down from $54.00) on shares of Biohaven in a report on Tuesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $54.23.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.